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Abstract
Objectives: Static mechanical allodynia (SMA), i. e., pain
causedbynormally non-painful static pressure, is a prevalent
manifestation of neuropathic pain (NP). Although SMA may
significantly affect thepatient’sdaily life, it is lesswell studied
in the clinical context. We aimed to characterize SMA in
women with chronic post-surgical NP (CPSNP) after breast
cancer surgery. Our objective was to improve understanding
of the clinical pictureof this prevalentpain condition. This is a
substudy of a previously published larger cohort of patients
with intercostobrachial nerve injury after breast cancer sur-
gery (Mustonen et al. Pain. 2019;160:246–56).
Methods: We studied SMA in 132 patients with CPSNP
after breast cancer surgery. The presence, location, and
intensity of SMA were assessed at clinical sensory exami-
nation. The patients gave self-reports of pain with the Brief
Pain Inventory (BPI). We studied the association of SMA to
type of surgery, oncological treatments, BMI, other pains,
and psychological factors. General pain sensitivity was
assessed by the cold pressor test.
Results: SMA was prevalent (84%) in this cohort whereas
other forms of allodynia were scarce (6%). Moderate-to-
severe SMA was frequently observed even in patients who
reportedmild pain in BPI. Breast and the side of chest were
the most common locations of SMA. SMA was associated
with breast surgery type, but not with psychological fac-
tors. Severe SMA, but not self-reported pain, was associ-
ated with lower cold pain tolerance.
Conclusions: SMA is prevalent in post-surgical NP after
breast cancer surgery and it may represent a distinct NP
phenotype. High intensities of SMA may signal the pres-
ence of central sensitization.
Implications: SMA should be considered when examining
and treating patients with post-surgical NP after breast
cancer surgery.
Keywords: breast cancer; evoked pain; neuropathic pain;
pain intensity; static mechanical allodynia.
Introduction
Neuropathic pain (NP) is a predominant component in
chronic post-surgical pain [1]. With a prevalence ranging
from 14–31%, chronic post-surgical NP (CPSNP) is espe-
cially common after breast cancer surgery and may persist
for several years [1–3]. Compared with other types of
chronic pain, chronic NP is often more burdensome to
patients and leads to decreased quality of life [4, 5].
The symptoms of NP are highly variable in terms of both
sensory qualities and pain descriptors. Patients may experi-
ence spontaneous or evoked pain, or a combination of these
[6, 7].Differentpain typesandsensoryalterationsmay involve
distinct pathophysiological mechanisms [8–10]. Recent at-
tempts in NP research have focused on identifying patient
subsetswhomayresponddifferently to treatments [7,8, 11, 12].
Allodynia is a type of evoked painwhere pain is elicited
by a normally non-painful stimulus. Different forms of
allodynia are prevalent among NP patients [13]. Static me-
chanical allodynia (SMA), refers to pain evoked by a nor-
mally innocuous sustained blunt pressure stimulus. The
prevalenceofpressure-evokedpainwas52%ina studyofNP
patients with various etiologies [14]. SMA is likely mediated
by sensitized C-fibers and possibly A-delta fibers, and its
pathophysiology may differ from other forms of allodynia
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(e. g. punctate or dynamic mechanical allodynia) [13, 15].
Both peripheral and central sensitization mechanisms may
contribute to the pathophysiology of SMA [16, 17].
The clinical impact of SMA has remained less well
studied [13]. We have previously reported that pain evoked
by static pressure was highly prevalent among patients
with CPSNP after breast cancer surgery and that it could be
clearly demonstrated during clinical examination [3].
Similarly, another study on chronic post-surgical pain after
breast cancer operations reported lower thresholds for
pressure pain at the painful surgical area [18]. These results
suggest that SMA may play a significant role in the symp-
tomology of CPSNP after breast cancer surgery.
In the current study, we aimed to characterize SMA in
women with CPSNP after breast cancer surgery in order to
assess how this pain type relates to the pain experience in
CPSNP. Our objective was to thoroughly characterize the
SMA phenotype by studying the prevalence, intensity and
location of SMA assessed during clinical sensory examina-
tion in comparison with self-reported pain, i. e., pain re-
ported in a pain questionnaire. We also tested how SMA
associates with previously reported common risk factors of
persistent post-surgical pain, including surgery type, onco-
logical treatments, and psychological factors [19]. In addi-
tion, we tested whether SMA associates with general pain
sensitivity as measured with the cold pressor test (CPT),
which may reflect central sensitization [3, 20]. With these
measures, we aimed to broaden the understanding of the
pain experience in CPSNP, which may improve patient
characterization and lead tomore individualized treatments.
Methods
Patients
We studied 132 breast cancer operated patients who fulfilled the diag-
nostic criteria [21] ofdefiniteNP.Thepatientswereclinicallyassessedona
research visit during 2014–2016, 4–9 years after surgery. Patient selec-
tion, diagnostic steps, and clinical sensory examination have previously
been described in detail [3]. Sensory examination covered the whole
upper body and included the following: static mechanical allodynia by
finger compression, dynamic mechanical allodynia by a painter’s brush,
tactile sensation by a cotton tuft, pinprick sensation by a sharp wooden
cocktail stick, and cold and warm sensation by a metal roller.
After breast cancer surgery, the neuroanatomically plausible
area for NP includes the operated breast and the area of intercosto-
brachial nerve (ICBN) innervation (axilla, upper side of the chest,
lateral breast, or upper medial arm) [22].
To meet the NP grading system criteria [21], alterations in at least
one sensory modality in the neuroanatomically plausible area of pain
were required in the clinical examination. All patients had a surgeon-
verified ICBN resection. To fulfill the criteria for definite NP, they all
had pain and sensory changes in the area of ICBN innervation. The
number of definite NP patients assessed in our previous studywas 135,
but we excluded three patients from the current analysis due to
missing data in the intensity of SMA.
Pain measurements
We use the terms SMA (static mechanical allodynia) [23] for pain
evoked by light static pressure by finger compression at clinical sen-
sory examination and “self-reported pain” for pain reported by the
patients in the pain questionnaire Brief Pain Inventory (BPI). We use
the term “other pain” for pain outside the surgical and nearby area
(e. g. back pain, joint pain etc.). From here on, we will use these terms
to describe these different pain conditions.
We used a simple bedside test with the following standardiza-
tion: first, the examiner presented the finger pressure to neutral re-
gions such as the forehead and the sternum, so that the patient could
experience a normal blunt pressure sensation. The finger pressure
lasted for about 2 s, so no temporal summation was likely to develop.
The pressurewas light and it was performed in the samemanner for all
patients by the same examiner. The tip of the digit was perpendicular
to the skin. SMA was tested all over the upper body in about 5 cm
intervals andmore densely (about 2 cm intervals) in the breast and the
plausible innervation area of the ICBN.
If SMA was observed during the clinical sensory examination,
patients rated the pain intensity by Numerical Rating Scale (NRS 0–
10). For the self-reported pain intensity, the patientswere asked to rate
theworst pain in the neuroanatomically plausible area during the past
week with a NRS 0–10 by using the BPI [24, 25]. The patients reported
the intensity of other pains similarly, the worst pain intensity by BPI
during past week with NRS 0–10. The 11-point NRS is a widely-used
tool to assess pain intensity in chronic pain patients, including those
with chronic NP [26–28]. The anchors used in both ratings were 0 for
“no pain” and 10 for “the worst imaginable pain”. We considered NRS
1–3 asmild,NRS4–6 asmoderate andNRS 7–10 as severe pain [29, 30].
The clinical examiner was blinded to the BPI reports and the ICBN-
status (total or partial resection) of the patients [3].
The clinical examiner marked the location of SMA on a upper
torso body map. Pain drawings for patients were on similar type of
body maps. For illustration, we divided the neuroanatomically plau-
sible area into sections on the body map and gave number of patients
reporting pain within each section.
Clinical and psychological variables
Multiple risk factors involve in chronic post-surgical pain and NP after
breast cancer surgery. Although the results have varied across studies,
certain patient – and treatment – related factors and psychological
factors have often emerged as significant [19, 31–36]. Based on these
findings, we selected the following variables for our analysis: age;
body mass index (BMI); other pains (0–10/10 NRS); type of breast
surgery; type of axillary surgery; type of ICBN resection (total/partial);
radiotherapy (yes/no); chemotherapy (yes/no); depressive symptoms
(Hospital Anxiety and Depression Scale, HADS, total score for
depression); anxiety (HADS, total score for anxiety); pain cata-
strophizing (Pain Catastrophizing Scale, PCS, total score). Since the
follow-up time varied from 4 to 9 years, the time from surgery was also
included in the analysis.
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Since the studied patients are a subgroup from a previous larger
prospective cohort of women treated for breast cancer [37], the infor-
mation concerning surgery and breast cancer treatments was avail-
able. All patients had undergone either mastectomy or breast-
conserving surgery (BCS) and axillary lymph node dissection (ALND),
or sentinel lymphnode biopsy (SLNB). All eligible patients (n=132) had
a surgeon-verified ICBN resection during breast cancer surgery. The
operating surgeon reported the type of ICBN resection (partial or total).
The surgical process has been described in detail previously [3].
During the research visit, the research nurse recorded age, time
from index surgery, and BodyMass Index (BMI) and the patients filled
HADS and PCS questionnaires.
Cold pressor test
We performed a CPT to study sensitivity to cold pain. In the CPT, the
patients immersed their contralateral (to the side of breast cancer
operation) hand into circulating cold water (+2–4 °C) bath (JULABO
USA Inc., Allentown, PA) up to the wrist for the maximum time
tolerated but no longer than 90 s. During the CPT, patients reported
pain intensity every 15 s and at the end of CPT on anNRS 0–10 by using
the same anchors as for the pain in the surgical area.
Statistical analysis
We used SPSS 22.0 version for Windows (SPSS Inc., Chicago, IL., USA)
to perform all statistical analyses. p-values below 0.05 were consid-
ered statistically significant. For bivariate analysis, we used Spear-
man’s rho (rs) for correlation of continuous variableswith the SMAand
self-reported pain intensity ratings. Additionally, the Mann–Whitney
U-test or Kruskal–Wallis test was applied for the categorical variables.
For multivariate analysis, linear regression was applied to test the
association of the intensity of SMA and self-reported pain to clinical
and psychological variables. We added all studied variables to one
regression model to investigate the multivariate association of the
variables on SMA and self-reported pain.
We used the Cox regression analysis to assess the CPT. We used
time towithdrawal as the time to event. Datawere right-censored if the
participant endured the CPT the maximum 90 s. For the outcome
variable of self-reported pain or SMA intensity, we categorized as no to
low (0–3 NRS), moderate (4–6 NRS), and severe (7–10 NRS). The Cox
regression models were adjusted for age, BMI, “other pain” and self-
reported/SMA. Self-reported pain was used to adjust for the model of
SMA, and vice versa.
Results
Patient characteristics
The demographic factors, cancer – and treatment-related
factors, other pains, psychological factors and basic labo-
ratory data of the studied patients have been described in
detail previously [3]. All 132 patients had either self-re-
ported pain, evoked pain at clinical examination, or both in
the neuroanatomically plausible area. Static mechanical
allodynia tested by finger compression was by far the most
frequent type of evoked pain [3].
111 (84.1%) patients presented with SMA. 9/132 (6.8%)
presentedwith some other formof allodynia or hyperalgesia
at clinical sensory examination: pinprick hyperalgesia in
six, dynamic mechanical allodynia in three, allodynia to
light touch in two, and cold allodynia in one. All patients
with other forms of allodynia also presented with SMA.
84/132 (63.6%) patients presented with both self-re-
ported pain and SMA in the neuroanatomically plausible
area. 21/132 (15.9%) patients had only self-reported pain,
and 27/132 (20.5%) patients had only SMA pain (Figure 1A).
The overlap of self-reported pain and SMA intensities
is illustrated in Figure 1B. 20/132 (15%) patients reported
moderate to severe (NRS 4–10) pain in both intensity rat-
ings and 38/132 (29%) had nomore thanmild pain (NRS 0–
3) in both pain ratings. Only 9/132 (7%) patients had
moderate to severe self-reported pain accompanied with
no tomild intensity SMA. In contrast, 65/132 (49%) patients
had moderate to severe SMA accompanied with no to mild
self-reported pain. Only 7/132 (5%) of the patients reported
severe (NRS 7–10) self-reported pain whereas SMA with
severe intensity was reported by 35/132 (27%).
Location of pain in the neuroanatomically
plausible area
Figure 2 illustrates the location of self-reported pain (A)
and SMA (B) pain within the neuroanatomically plausible
area and in the nearby areas. The neuroanatomically
plausible area is marked with a dotted line.
62/132 (47%) and 70/132 (53%) of the surgeries were
performed on the right and left sides, respectively. For
clarity, all surgeries are shown on the right side in Figure 2.
Breast and upper side of the anterior chest wall were
themost common locations for both self-reported pain and
SMA (Figure 2). Self-reported pain was frequently located
in the axilla: 43/132 (33%) gave self-reported pain in the
anterior and 31/132 (23%) in the posterior side of axilla.
SMA was less frequently found in the axilla: 16/132 (12%)
patients had SMA in the anterior and 9/132 (7%) in the
posterior side of axilla.
Self-reported pain was widely distributed within the
neuroanatomically plausible area and the nearby areas
(Figure 2). 93/132 (70%) patients self-reported pain in more
than one of the locations depicted in Figure 2. In contrast,
SMA was more confined within breast and the upper
anterior chest wall (Figure 2). 59/132 (45%) patients had
SMA pain in more than one location.
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Factors associating with the intensity of
static mechanical allodynia and self-
reported pain
The results for the bivariate analysis and multivariate
analysis (linear regression) are presented in Table 1.
In the bivariate analyses, more intense other pains,
higher BMI, BCS as breast surgery type, radiotherapy, and
depressive symptoms were associated with higher in-
tensities of SMA (Table 1). However, in the multivariate
analysis, only the association to breast surgery type
remained significant (Table 1).
In contrast to SMA, the intensity of self-reported pain did
not associate with surgery – and treatment – related factors
(Table 1). Higher intensities of self-reported pain were asso-
ciated with “other pain” – intensity, higher psychological
burden, and pain catastrophizing. However, in the linear
regression model, the intensity of “other pains” overrode the
effect of the psychological variables (Table 1).
Age and time from surgery showed no correlation
with either SMA or self-reported pain intensities. There
was no correlation between self-reported pain and SMA
intensities. However, we observed a statistically-signifi-
cant positive correlation (rs=0.24, p=0.026) for patients
who presented with both self-reported pain and SMA
(n=84).
Cold pain sensitivity
Patients with severe (NRS 7–10) SMA were significantly
more sensitive to cold pain, i. e., they aborted the CPT after
a shorter time than did patients with no to mild intensity
SMA (Figure 3, Table 2). The association remained
Figure 2: Location of static mechanical
allodynia and self-reported pain in the
neuroanatomically plausible and nearby
area. N=132. For clarity, right side is
illustrated as the surgical side for all
patients. The neuranatomically plausible
area (breast and the area of ICBN
innervation) is shown with a dotted line. (A)
static mechanical allodynia and (B) self-
reported pain.
Figure 1: Prevalence and intensity of static
mechanical allodynia and self-reported
pain. (A) The prevalence and overlap of of
static mechanical allodynia and self-
reported pain. The Venn diagram is only
illustrative and it has not been drawn to
scale. (B) The overlap of no-mild (NRS 0–3)
and moderate-severe (NRS 4–10) of static
mechanical allodynia and self-reported
pain. NRS, Numerical Rating Scale.
686 Mustonen et al.: Post-surgical neuropathic pain after breast cancer treatments
Table : Association of the intensity of static mechanical allodynia and self-reported pain to the clinical and psychological variables.




Bivariate analysis Multivariate analysis Bivariate analysis Multivariate analysis
rS or Median
(IQR)





– – – – . . . .
Self-reported pain
intensity (NRS –)
. . . . – – – –
Age (years) . . −. . . . . .
BMI (kg/m) . . −. . . . . .
Time from surgery (months) . . −. . −. . −. .
“Other pain” intensity
(NRS –)a
. . . . . <. . <.
Breast surgery type
BCS  (–) <. . <.  (–) . −. .
Mastectomy  (–) [ref.]  (–) [ref.]
Axillary surgery type
ALND  (–) . . .  (–) . . .
SLNB  (–) [ref.]  (–) [ref.]
ICBN resection type
Total  (–) . . .  (–) . −. .
Partial  (–) [ref.]  (–) [ref.]
Radiotherapy
Yes  (–) <. . .  (–) . −. .
No  (–) [ref.]  (–) [ref.]
Chemotherapy
Yes  (–) . . .  (–) . . .
No  (–) [ref.]  (–) [ref.]
HADS-D, (total score)b . . . . . . . .
HADS-A (total score)c . . −. . . . . .
PCS (total score) d . . . . . <. . .
Adjusted R . .
a
 missing values.
b One missing value.
c One missing value.
d Four missing values.
p-values<. are shown in bold. Bivariate analysis reports the correlation for continuous variables to the intensity (– NRS) of static
mechanical allodynia and self-reported pain. For categorical variables, the median and IQR are reported. Due to the missing values, n= for
linear regression. ALND, axillary lymph node clearance; BMI, Body Mass Index; BCS, breast conserving surgery; HADS-A, Hospital Anxiety and
Depression Scale, Anxiety; HADS-D, Hospital Anxiety and Depression Scale, Depression; IQR, interquartile range; PCS, Pain Catastrophizing
Scale; rS, Spearman’s rho; SLNB, sentinel lymph node biopsy.
Figure 3: Cox regression analysis. Survival
curves for cold pain tolerance for patients
with no-mild (NRS 0–3), moderate (NRS 4–
6), and severe (NRS 7–10) static mechanical
allodynia (A) and self-reported pain (B).
NRS, Numerical Rating Scale.
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statistically significant even after multivariate adjustment
(Table 2). Patients with moderate (NRS 4–6) SMA showed
no significant increase in cold pain sensitivity (Table 2).
Patients with moderate (NRS 4–6) or severe (NRS 7–10)
self-reported pain were not more sensitive to cold pain than
patientswithnoormild (NRS0–3) self-reportedpain (Table2).
Discussion
In our cohort of post-surgical NPpatients, the prevalence of
SMA was high (84%) and overlap with self-reported pain
common (64%). In contrast, the prevalence of other types
of allodynia was low (6%).
Surprisingly, patients who self-reported none or mild
pain anyhow presented with high intensities of SMA in the
neuroanatomically plausible area. SMA was frequently
confined to the areas of breast and side of chest whereas
self-reported pain was more widely distributed within the
operative and nearby areas.
Risk factors of post-surgical pain presented differently
in SMA and self-reported pain. Higher intensities of SMA
were observed in patients with BCS as the type of breast
cancer surgery. Psychological factors did not associate
with SMA intensity in multivariable analysis. Furthermore,
patients with severe SMA showed increased general pain
sensitivity in CPT. Overall, these results suggest that SMA
represents a distinct pain type that frequently contributes
to the symptomology of post-surgical NP in breast cancer
survivors. It may reflect the presence of central sensitiza-
tion and is not associated by psychological burden.
SMA is a common finding in NP conditions with a
prevalence of 36–52% in NP of various etiologies and 51%
in NP after peripheral nerve injury [14, 38, 39]. Nociceptor
sensitization and altered function of spinal inhibition may
play a role in SMA [13, 15, 40]. This is in linewith our results
linking higher intensities of SMA to central sensitization,
reflected as increased cold pain sensitivity. These results
may help to identify phenotypes within NP patients and in
treatment strategies.
Nearly 50%of the patients in our cohort presentedwith
moderate to severe evoked pain, but self-reported painwas
only mild or none of it. This may indicate that patients may
avoid even severe pain for blunt pressure in everyday life
by behavioral adjustments, e. g., by avoiding pressure-
provoking activities or clothing. Some of our patients
shared these experiences with the examiner. Few studies
have assessed the impact of SMAondaily life. In a Japanese
population-based study, the report of pressure-pain in the
pain detect questionnaire was associated with lower
quality of life in patients with chronic NP [41]. Our results
call for further studies on how different pain types affect
the life of breast cancer survivors.
In the body maps, SMA was clearly more confined to
the neuroanatomically plausible area compared with self-
reported pain. This is in line with previous reports stating
that SMA exhibits mainly in the areas of primary hyper-
algesia (i. e., the area of damaged nerve endings) [13, 42].
This is in contrast to other forms of allodynia (thermal,
punctate), which often spread to the areas of secondary
hyperalgesia [13].
Although all patients had a surgeon-verified ICBN-
resection, the breast region was also important for SMA
pain especially in patients with BCS. We have previously
reported that BCS associates significantly with the
development of NP after ICBN resection [3]. Here, we
Table : Cox’s regression models for cold pain tolerance: patients with no to mild (NRS –), moderate (NRS –), and severe (NRS –)
static mechanical allodynia and self-reported pain.
n Unadjusted model Adjusted modela
HR CI (%) p-value HR CI (%) p-value
Static mechanical allodynia
NRS –  . .
NRS –  . .–. . . .–. .
NRS –  . .–. . . .–. .
Self-reported pain
NRS –  . .
NRS –  . .–. . . .–. .
NRS –  . .–. . . .–. .
p-values < . are shown in bold.
aBoth models were adjusted for: age, BMI, other pain (NRS –). n= for adjusted models. The static mechanical allodynia model was
adjusted for self-reported pain and the self-reported pain model was adjusted for static mechanical allodynia.
BMI, Body Mass Index; CI, confidence interval; HR, hazard ratio; NRS, Numerical Rating Scale.
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observed that BCS associated with higher intensities of
SMA, but not with self-reported pain. The reason for
this is unclear. Radiotherapy could mediate the effect,
since it is commonly administered after BCS. However,
radiotherapy did not show significant association in
multivariable analysis. All in all, our findings are in line
with a recent study on persistent post-surgical pain after
breast cancer surgery reporting lower pressure pain
thresholds in quantitative sensory testing in patients
with BCS [18]. The authors referred to the intact noci-
ceptor hypothesis as a possible mechanistic explanation
to the findings.
Perception of chronic pain is influenced by an affective
component, encompassing mood and beliefs [43–45]. In
line with this, anxiety, depression, and pain catastrophiz-
ing have emerged as risk factors for persistent post-surgical
pain after breast cancer surgery [19]. In our study, higher
intensities of self-reported pain positively associated with
depressive symptoms, anxiety, and pain catastrophizing,
although the association was mediated by “other pains” in
our multivariate model (Table 1). In contrast, more severe
SMA did not associate with anxiety or pain catastrophizing
and the positive correlation to depressive symptoms was
rendered non-significant in multivariable analysis. Our
results are in linewith a previous study [44] showing that in
NP patients, psychological factors are stronger predictors
for spontaneous pain than for evoked pain supporting the
hypothesis of distinct pain types and psychological corre-
lates.
Different forms of allodynia are common inNPpatients
[13]. For example, the prevalence of dynamic mechanical
allodynia (i. e., pain caused by light brushing of skin)
ranged from 12–49% in different NP etiologies in a large
study based on quantitative sensory testing [38]. However,
in our cohort of breast cancer treated patients with CPSNP,
other forms of allodynia were scarce (6%) at clinical sen-
sory examination. This is in line with previous studies on
sensory dysfunction of post-surgical pain after breast
cancer surgery [18].
Sensory profiling has gained recognition in NP
research as a means to pursue more individualized and
mechanism-based treatment [8, 14]. Previous clinical trials
have used different forms of allodynia either to predict
treatment responses in post hoc analyses [46–49] or as an
outcome measure [50]. However, studies that have
assessed mechanical allodynia, have mainly included
punctate or dynamic mechanical allodynia. These may
differ mechanistically from SMA [13, 15] and are rare in our
cohort of CPSNP after breast cancer surgery. Further
studies are needed to assess whether SMA could be used to
predict treatment responses in this patient group. For now,
the pharmacological treatment of neuropathic pain with
SMA is based on the general guidelines for treating
neuropathic pain [51]. Patients can be advised to avoid
triggers of SMA, e. g., pressure by tight clothing, and apply
psychological or physiotherapeutic interventions, when
needed.
Strengths and limitations of the study
Strengths of the study include a fairly large cohort of well
phenotyped NP patients with extensive clinical and psy-
chological data. The patients underwent a thorough clin-
ical examination andwere classified according to the latest
NP grading system.
As limitations, our cohort consisted of women treated
for breast cancer. Therefore, our results may not be
generalized to men or to other traumatic nerve injuries.
Secondly, we compared SMA to self-reported pain assessed
by BPI, which does not distinguish spontaneous and
evoked components of pain and may therefore include
both components.
Conclusions
Our results show that SMA is an important component of
post-surgical NP after breast cancer treatment whereas
other forms of allodynia are scarce. A clinician can readily
test SMA in a standard clinical setting and it may provide
an easy method to characterize patients. We demonstrated
that high intensities of SMA associate with general sensi-
tivity to experimental pain and may reflect central sensi-
tization. Our results confirm previous findings that NP
consists of different pain components that may differ be-
tween individuals. This may be important to consider in
individualized pain management.
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